Health Notices




NEW ZEALAND GAZETTE

No. 56

The Special Needs of Maori and other Particular Communities of People

The Crown’s objective is that the Public Health Commission should:

(1) have regard to the Crown’s policy direction for Maori expressed in the document Whaia te ora mo te iwi;

(2) seek to improve the health status of Maori so that they will enjoy the same level of health as non-Maori;

(3) purchase services that to the greatest extent possible recognise the special needs and cultural values of the eligible persons concerned, in particular Maori, Pacific Island people, and people with disabilities.

Dated at Wellington this 19th day of May 1994.

J. M. SHIPLEY, Minister of Health.

go4141


Medicines Act 1981

Consent to the Distribution of a Changed Medicine

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Cimetidine 200 mg Tablet SmithKline Beecham Pharmaceuticals, Dandenong, Victoria, Australia Tagamet

Dated this 2nd day of June 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go4218


Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Glycerine 69.7% w/w in 1g, 2g and 4g Suppositories Daniels Pharmaceuticals Limited, Derby, England
Iomeprol 30.62% w/v containing 150 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 150
Iomeprol 40.82% w/v containing 200 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 200
Iomeprol 51.03% w/v containing 250 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 250
Iomeprol 61.24% w/v containing 300 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 300
Iomeprol 71.44% w/v containing 350 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 350
Iomeprol 81.65% w/v containing 400 mg iodine per ml Solution for injection Bracco Industria Chimica S.p.A., Milano, Italy Iomeron 400
Thymol 0.016 mg, menthol 3.28 mg, eucalyptol 0.451 mg, guaiaicol 0.016 mg, terpinol 0.016 mg Lozenge (eucalyptus and menthol, and lemon flavours) Laboratoires Thelfar, Pont des Charetteux, Uzes, France Valda Pastilles
Note: This replaces the entry in the notice published in the New Zealand Gazette, 29 April 1993, No. 58, page 1088, notice number 3436.
Tiaprofenic acid 300 mg Suppository Roussel SA, Brussels, Belgium Surgam

Dated this 2nd day of June 1994.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1991.

go4219



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1994, No 56


NZLII PDF NZ Gazette 1994, No 56





✨ LLM interpretation of page content

🏥 Notice to the Public Health Commission of the Crown’s Objectives in Relation to Public Health (continued from previous page)

🏥 Health & Social Welfare
19 May 1994
Health and Disability Services Act, Public Health Commission, Crown's Objectives, Health Status, Child Health, Maori Health, Mental Health, Physical Environmental Health
  • J. M. Shipley, Minister of Health

🏥 Consent to the Distribution of a Changed Medicine

🏥 Health & Social Welfare
2 June 1994
Medicines Act 1981, Cimetidine, Tagamet, SmithKline Beecham
  • C. Lovelace, Director-General of Health

🏥 Consent to the Distribution of New Medicines

🏥 Health & Social Welfare
2 June 1994
Medicines Act 1981, Glycerine, Iomeprol, Iomeron, Thymol, Valda Pastilles, Tiaprofenic acid, Surgam
  • C. Lovelace, Director-General of Health